SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs Q3 resultsrecord revenue and its first adjusted-EBITDA-profitable quarterare driving discussion, with traders highlighting Quake AI and Northern Data growth. The reaction is mixed: bulls point to the results and short interest, while skeptics question cash needs, financing, and potential delays to planned data-center capacity.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis quarterly results and outlook are driving debate, with traders focused on a steep revenue miss and guidance below expectations as they question the companys valuation and commercialization timeline. Others point to technical progress and government support, while some are trading a rebound after the selloff.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,959,453.18587388 with 16,959,453.64420722 in circulation. The last known price of Zcash is 1,033.61575403 USD and is down -11.66 over the last 24 hours. It is currently trading on 670 active market(s) with $1,322,935,861.71 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile pullback after a strong rally, with traders debating whether it reflects profit-taking and an unwind or broader crypto-market weakness. Bearish posts call the move a rug pull and expect further losses, while bullish traders view the dip as a buying opportunity and continue accumulating.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors Q3 call reaffirmed confidence in deramiocel and said its FDA application for Duchenne muscular dystrophy is in final review ahead of the Nov. 22 decision, keeping the approval outcome as the dominant focus. Many traders read managements comments and launch preparations as encouraging, while others stress that approval is uncertain and a rejection remains a major risk.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff and rebound are being debated amid reports about CEO Jensen Huangs alleged relationship with someone described as linked to Chinese intelligence, raising trader concerns about leadership, investigations and chip-export exposure. The Baird downgrade and questions about AI spending add to caution, while bulls argue that CoreWeaves results support continued demand and view the pullback as temporary noise.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call drew attention for its shift toward recurring memory-technology licensing revenue, with traders also parsing the CEOs comments as a possible hint of a future SK Hynix deal. Many were bullish on the stronger financial footing and expected future payments, while others noted the results missed some published expectations and questioned lower product sales; an Hynix agreement remains unconfirmed.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras Q3 results and earnings call are driving discussion, with traders highlighting KOMZIFTIs growing prescriptions and patient starts, alongside an EPS beat. Reactions are broadly favorable to the launch and managements rebuttal of J&Js competing-drug data, though some remain cautious about competition and the stocks weak price action.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected Q3 results and raised outlook, alongside a financing plan centered on customer prepayments rather than new unsecured debt, drove attention and optimism about AI-computing demand. Traders welcomed the update and speculated about short covering, while others argued that heavy debt, capital spending and continuing losses leave financing and profitability risks unresolved.

Bittensor (TAO) is a cryptocurrency launched in 2021and operates on the Bittensor platform. Bittensor has a current supply of 21,000,000 with 11,714,062.3012452 in circulation. The last known price of Bittensor is 218.6907284 USD and is down -1.27 over the last 24 hours. It is currently trading on 338 active market(s) with $106,454,109.48 traded over the last 24 hours. More information can be found at https://bittensor.com.

Bittensor

TAO is drawing attention amid crypto-market weakness and a recent pullback, with traders debating whether to wait for further downside or buy the dip. Long-term bulls point to Bittensors decentralized-AI and subnet potential, while skeptics say adoption and sustainable revenue still need to prove the thesis.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas comments projecting weaker DefenCath reimbursement through 2027 after the TDAPA transition triggered a sharp selloff and dominate discussion. Traders are divided: bears worry about lower payments, slower uptake and competition from ClearGuard, while bulls argue DaVitas estimates are preliminary and point to CMSs $8.32 Q1 2027 add-on rate and the companys cash position; Medicare Advantage coverage remains a key uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kingstone Companies Q3 2026 Earnings Call Transcript

Kingstone Companies (NASDAQ:KINS) reported third-quarter financial results on Friday. The transcript from the company's third-quarter earnings call has been provided below.Benzinga APIs provide real-time access toread more...

Kingstone Companies (KINS) Expected to Announce Quarterly Earnings on Thursday

Kingstone Companies (NASDAQ:KINS) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Insider Selling: Kingstone Companies (NASDAQ:KINS) Director Sells 13,500 Shares of Stock

Kingstone Companies, Inc (NASDAQ:KINS - Get Free Report) Director William Yankus sold 13,500 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an...

Kingstone Companies (NASDAQ:KINS) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen raised Kingstone Companies from a "hold" rating to a "buy" rating in a research note on Saturday...

Kingstone Companies (NASDAQ:KINS) Director William Yankus Sells 13,500 Shares

Kingstone Companies, Inc (NASDAQ:KINS - Get Free Report) Director William Yankus sold 13,500 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $18.00, for a total value of $243,000.00. Following the transaction, the director directly owned...

Kingstone Companies (NASDAQ:KINS) Share Price Passes Above 50-Day Moving Average   - Should You Sell?

Kingstone Companies (NASDAQ:KINS) Stock Passes Above Fifty Day Moving Average - Time to Sell...

Kingstone Companies (NASDAQ:KINS) Stock Crosses Below 200 Day Moving Average - Should You Sell?

Kingstone Companies (NASDAQ:KINS) Shares Pass Below Two Hundred Day Moving Average - Here's What Happened...

Kingstone Companies (NASDAQ:KINS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Kingstone Companies from a "buy" rating to a "hold" rating in a research report on Saturday...

Kingstone Companies Q4 Earnings Call Highlights

Kingstone Companies (NASDAQ:KINS) used its fourth-quarter earnings call to highlight what management described as the most profitable quarter and full year in the insurer's history, driven by strong...

Kingstone Companies (NASDAQ:KINS) Releases FY 2026 Earnings Guidance

Kingstone Companies (NASDAQ:KINS) updated its FY 2026 earnings guidance. The company provided EPS guidance of 2.200-2.900 for the period, compared to the consensus estimate of 2.500...

Kindred Biosciences is a veterinary biotechnology company, focuses on developing therapies for dogs, cats, and horses. It develops canine, feline, and equine antibodies for the treatment of diseases in companion animals. Its strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. Their mission is to bring innovative biologics to veterinary medicine because they believe their pets deserve the same kinds of safe and effective medicines that human family members enjoy. The company was incorporated in 2012 and is based in San Francisco, California.

Kindred Biosciences Inc

Neutral Sentiment

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Feed

News

Sentiment

Fundamentals

Info

KIN News